St-Georges, Alexandre https://orcid.org/0009-0005-2135-7652
Houle, Alexi
Cenci, Thomas
Giroux, Jean-Sébastien
Toussaint, Maxime
Thibaudeau, Christian
Auger, Etienne
Croteau, Étienne
Cunnane, Stephen
Lecomte, Roger
Michaud, Jean-Baptiste
Funding for this research was provided by:
Alliance de recherche numérique du Canada (2630, 4063, 5036)
Natural Sciences and Engineering Research Council of Canada (RGPIN-2019-06187 and RGPIN-2016-05036)
Ministère de l’Économie, de l’Innovation et des Exportations du Québec (FACS-008)
Canadian Network for Research and Innovation in Machining Technology, Natural Sciences and Engineering Research Council of Canada (RGPIN-2016-05036)
Article History
Received: 18 July 2025
Accepted: 12 June 2026
First Online: 1 September 2026
Declarations
Ethics approval and consent to participate: The data for this work was obtained from a study that was approved by the Institutional Review Board and Ethics Committees (Health and Social Services Center, Sherbrooke University Geriatrics Institute and the Centre hospitalier universitaire de Sherbrooke), protocol number: MP-22-2015-509. Written informed consent was obtained for all participants. The clinical protocol, registered at ClinicalTrials.gov , is NCT02551419 (Proof of Mechanism of a New Ketogenic Supplement Using Dual Tracer PET (Positron Emission Tomography) (BENEFIC)). Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
Competing interests: RL is both with the Université de Sherbrooke and a co-founder and Chief Scientific Officer of IR&T Inc., which funded part of this work through the Acuity-QC Consortium. SC consults for and has received research funding and research materials from Nestlé Health Science. He also consults for Cerecin. Other authors have no conflict of interest to declare relevant to the content of this article.